Search
Now showing items 1-10 of 17
Documento de consenso de la Sociedad Española de Ginecología y Obstetricia (SEGO) y el Comité Español Interdisciplinario para la Prevención Vascular (CEIPV): ventana de oportunidad: prevención del riesgo vascular en la mujer: resultados adversos del embarazo y riesgo de enfermedad vascular
(Sociedad Española de Ginecología y Obstetricia (SEGO), 2023)
[Resumen] Este documento resume la evidencia que existe entre los resultados adversos del embarazo (RAE), tales como son los trastornos hipertensivos,
el parto pretérmino, la diabetes gestacional, los defectos en el ...
RP11-362K2.2:RP11-767I20.1 genetic variation is associated with post-reperfusion therapy parenchymal hematoma: a GWAS meta-analysis
(MDPI, 2021-07-16)
[Abstract] Stroke is one of the most common causes of death and disability. Reperfusion therapies are the only treatment available during the acute phase of stroke. Due to recent clinical trials, these therapies may increase ...
Statistical analysis plan for the multicenter, open, randomized controlled clinical trial to assess the efficacy and safety of intravenous tirofiban vs aspirin in acute ischemic stroke due to tandem lesion, undergoing recanalization therapy by endovascular treatment (ATILA trial)
(Springer Nature, 2024-01-09)
[Abstract] Rationale: In-stent reocclusion after endovascular therapy has a negative impact on outcomes in acute ischemic stroke (AIS) due to tandem lesions (TL). Optimal antiplatelet therapy approach in these patients ...
Stroke prevention in patients with arterial hypertension: recommendations of the Spanish Society of Neurology's Stroke Study Group
(Elsevier, 2021-04-23)
[Abstract]
Objective: To update the recommendations of the Spanish Society of Neurology on primary and secondary stroke prevention in patients with arterial hypertension.
Development: We proposed several questions ...
A multitrait genetic study of hemostatic factors and hemorrhagic transformation after stroke treatment
(Elsevier, 2023-12-15)
[Abstract]
Background: Thrombolytic recombinant tissue plasminogen activator (r-tPA) treatment is the only pharmacologic intervention available in the ischemic stroke acute phase. This treatment is associated with an ...
Recommendations of the Spanish Society of Neurology for the prevention of stroke: interventions on lifestyle and air pollution
(Elsevier, 2021-03-27)
[Abstract]
Objective: To update the recommendations of the Spanish Society of Neurology regarding lifestyle interventions for stroke prevention.
Development: We reviewed the most recent studies related to lifestyle ...
Impact of COVID-19 outbreak on ischemic stroke admissions and in-hospital mortality in North-West Spain
(Sage, 2020-06-11)
[Abstract]
Background and purpose: Spain has been one of the countries heavily stricken by COVID-19. But this epidemic has not affected all regions equally. We analyzed the impact of the COVID-19 pandemic on hospital ...
Prevención de ictus en pacientes con diabetes mellitus tipo 2 o prediabetes: recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología
(Elsevier, 2020-09-24)
[Resumen] Objetivo. Actualizar las recomendaciones de la Sociedad Española de Neurología para la prevención del ictus en pacientes con DM-2 o prediabetes, analizando las evidencias disponibles sobre el efecto del control ...
Dyslipidemias and stroke prevention: recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology
(Elsevier, 2022-01)
[Abstract]
Objective: We present an update of the Spanish Society of Neurology's recommendations for prevention of both primary and secondary stroke in patients with dyslipidaemia.
Development: We performed a ...
Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol
(Sage, 2022-12-28)
[Abstract] Background: In-stent thrombosis after mechanical thrombectomy (MT) worsen outcomes in acute ischemic stroke (AIS) due to tandem lesions (TL). Although an optimal antiplatelet therapy is needed, the best approach ...
